

PATENT ATTORNEY DOCKET NO. 50026/012003

Certificate of Mailing: Date of Deposit: February 19, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Christine M. Colbert

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OF RECEIVED

Applicant:

Keiya Ozawa et al.

Art Unit:

1636 FEB **2 7** 2004

Serial No.:

09/905,592

Examiner:

R. Akhavan

Filed:

July 13, 2001

Customer No.:

21559

Title:

GENE THAT IMPARTS SELECTIVE PROLIFERATIVE ACTIVITY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the attached form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is information included in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office Action on the merits, but before 02/26/2004 SZEWDIE1 00000062 09905592

01 FC:1806

180.00 OP



receipt of a final Office Action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee of 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 19 Fishutty 2004

James D. DeCamp, Ph.D. Reg. No. 43,580

Rag. Mo. 52, 290

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045



RECEIVED

FEB 2 7 2004

Sheet 1 of 1

ABS			·			,		
SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE				Attorney Docket No. Serial No.		50026/012003 09/905,592		
					Applicant		Keiya Ozawa et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Filing Date		July 13, 2001		
				Group		1636		
(37 C.F.R. § 1.98(b))				IDS Filed		February 19, 2004		
U.S. PATENTS								
					- I			
Examiner's Initials	Patent Number	Issue Date	Patentee		Class	Subclass	Filing Date (If Appropriate)	
• FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION								
Examiner's Initials	Document Number	Publication Date		Country or Patent Office		Subclass	Translation (Yes/No)	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)								
	Anderson, "Human Gene Therapy" Nature 392(Supp.):25-30 (1998).							
	Cheok, "Cancer Fears Cast Doubts on Future of Gene Therapy" Nature 421:678 (2003).							
	Cui et al., "Inhibitory Effect of a Soluble Transforming Growth Factor β Type II Receptor on the Activation of Rat Hepatic Stellate Cells in Primary Culture" <i>Journal of Hepatology</i> 39:731-737 (2003).							
	Juengst, "What Next for Human Gene Therapy" BMJ 326:1410-1411 (2003).							
	Kakuta et al., "Inhibition of B16 Melanoma Experimental Metastasis by Interferon-γ through Direct Inhibition of Cell Proliferation and Activation of Antitumour Host Mechanisms," <i>Immunology</i> 105:92-100 (2002).							
	Kmiec "Gene Therapy" American Scientist 87:240-247 (1999).							
	Marcinkowska and Więdłocha "Steroid Signal Transduction Activated at the Cell Membrane: from Plants to Animals," Acta Biochimica Polonica 49(3):735-745 (2002).							
	Maruyama et al., "Proliferation and Erythroid Differentiation through the Cytoplasmic Domain of the Erythropoietin Receptor," <i>The Journal of Biological Chemistry</i> , 269(8):5976-5980 (1994).							
	O'Farrell et al., "IL-10 Inhibits Macrophage Activation and Proliferation by Distinct Signaling Mechanisms: Evidence for Stat3-Dependent and -Independent Pathways," <i>The EMBO Journal</i> 17(4):1006-1018 (1998).							
	Verma and Somia, "Gene Therapy-Promises, Problems and Prospects," Nature 389:239-242 (1997).							
	Wang et al., "Yeast Two-Hybrid System Demonstrates that Estrogen Receptor Dimerization Is Ligand-Dependent in Vivo," The Journal of Biological Chemistry, 270(40):23322-23329 (1995).							
	Wimmel et al., "Autocrine Growth Inhibition by Transforming Growth Factor β-1 (TGFβ-1) in Human Neuroendocrine Tumour Cells," <i>Gut</i> 52:1308-1316 (2003).							
EXAMINER DATE CONSIDERED								
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this								

form with the next communication to applicant.